Numinus Bioscience is at the forefront of psychedelic diagnostic testing, as a center for excellence in research and development of psychedelic product, and as a supplement to clinical trials for psychiatry. Health Canada licenses, scientific technologies, and state-of-the-art technology facilitate continuous innovation, while revenue from cannabis testing for high-end contracts is reinvested to further its psychedelic programs.

In addition to

Today’s announcement, Numinus includes in its recent development an application for amendment to its Health Canada- Controlled Drugs and Substances License. The current license allows for the testing, import and export, storage and distribution of MDMA, Psilocybin, Psilocin, DMT, and Mescaline as well as the implementation of new mycological research programs. The amendment will also allow for the commercialization of the fruit-bearing bodies of Psilocybe mushroom and the removal of clinical research principles and the development of standardized psychedelic supplement tests.

Numinus is also proud to announce the recent hiring of Sharan Sidhu, a management expert and policy advisor in high-growth industries, such as the Science Officer and General Manager. Sidhu brings extensive experience as a platform between academics, industry, and administrative offices to guide research objectives and compliance. He has been a key strategist in road map research, strategic planning, IP development, and development compliance requirements including LIMS, GLP / GMP, GACP, and ISO Standards.

"Sharan's experience and leadership is already crucial in establishing Numinus Bioscience as a center of excellence and a key player in the industry in delivering safe, evidence-based, easily accessible psychotherapy," said Payton mushroom online, CEO, Founder and Chairman. "We feel honored to have him join us in our work."

• Sidhu leads a team of successful scientific researchers including
• Dr. Bernd O. Keller, PhD
• (Advanced Analysis Methods), Dr. Kristina Grotzinger, PhD
• (Phytochemistry), and Judit Varga, MSc (Advanced Methods of Microbiology).

About Numinus

Numinus is a Vancouver-based healthcare company that develops an ecosystem of health solutions focused on developing and supporting safe, evidence-based, and psychedelic-assisted medical care. Numinus ecosystem units include Numinus Bioscience, Numinus R&D, and Numinus Health. Each unit makes separate, concerted efforts to accelerate formal, psychedelic-assisted therapeutic models and to establish Numinus as a trusted industry leader in maintaining the regulated release of these therapies.

Numinus Bioscience includes a 7,000-square-foot research and testing laboratory and multiple Health Canada licenses (with the subsidiary of Salvation Botanicals) including a B2B cannabis experimental drug license to support the company's psychedelic efforts. The company has a Merchant License that allows it to import, export, manage, and inspect MDMA, psilocybin, psilocin, DMT and mescaline as well as license to manufacture and export psilocybin from mushrooms. These licenses allow Numinus to support a growing number of studies with potential psychedelic-assisted psychological benefits through research projects, product development, and the provision and distribution of these materials.

• Numinus R&D begins to apply science and implement
• established relationships in order
• to collaborate to host studies, develop medical and clinical
• agreements, and contribute to regulatory authorization.

Numinus Health is dedicated to providing therapies that enhance and enhance the options mushroom online to people seeking sustainable physical, mental and emotional health - focusing on safe, evidence-based and affordable evidence-based therapies.